ALK and neoplasm: Lorlatinib induced complete tumor regression in both crizotinib-resistant and sensitive neuroblastoma-derived xenografts harboring F1174L, F1245C or R1275Q ALK mutations, demonstrating lorlatinib’s potential to overcome crizotinib resistance.